Compare Cassava Sciences Inc (FLNA) vs Tesla, Inc. (TSLA) Price & Performance

Cassava Sciences IncTrade

Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Tesla, Inc. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Tesla, Inc. trades at $333.35 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 27434.6× Cassava Sciences Inc's market cap, and Tesla, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

	FLNA	TSLA
Market Cap	$47.75M	$1.31T
Sector	Health	Consumer Cyclical
52-Week High	$4.64	$489.88
52-Week Low	$0.87	$298.16
Enterprise Value	-$34.93M	$1.29T

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

No Aura AI signal available yet.

Tesla, Inc.

Tesla (TSLA) trades at $330.87, up 0.7% on the day, with a bearish technical signal from moving averages and a mixed fundamental picture. The stock shows high valuation multiples (P/E 308.16, P/S 11.36) amid declining profitability, with net income margin falling to 3.67% in 2025 from 15.49% in 2023. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, but Q2 2026 earnings missed expectations.

Outlook remains polarized: analyst consensus price target of $393.87 suggests 19% upside, but high valuation and margin compression pose risks. Key catalysts include autonomy advancements and energy/robotics growth, while competition and execution challenges weigh on sentiment. The stock's trajectory hinges on delivering AI-driven revenue streams beyond automotive.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

FLNA

View details →

TSLA

Investor Ron Baron predicts SpaceX could reach a $40 trillion valuation in 15 years, echoing his successful Tesla bet.24/7 Wall Street · 4 hours agoBullish Tesla shares fall 26% YTD, seen overvalued at $333 amid weak margins and costly growth bets.24/7 Wall Street · 4 hours agoBearish Tesla CEO Musk's 2025 pay plan could skip milestones if Tesla is acquired, potentially unlocking $824B payout.24/7 Wall Street · 4 hours agoNeutral View details →

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.